<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00055848</url>
  </required_header>
  <id_info>
    <org_study_id>CALGB-150008</org_study_id>
    <secondary_id>CALGB-150008</secondary_id>
    <secondary_id>CDR0000271314</secondary_id>
    <nct_id>NCT00055848</nct_id>
  </id_info>
  <brief_title>Genetic Study of Familial Factors in Patients With Colon Cancer</brief_title>
  <official_title>Familial Factors in the Development of Colon Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alliance for Clinical Trials in Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Alliance for Clinical Trials in Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Genetic studies may help in understanding the genetic processes involved in the&#xD;
      development of some types of cancer.&#xD;
&#xD;
      PURPOSE: Clinical trial to study the cancer-related genes in patients who have colon cancer&#xD;
      or adenomatous polyps.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Identify human colon neoplasia susceptibility genes in patients with colon cancer or&#xD;
           adenomatous polyps.&#xD;
&#xD;
        -  Correlate the inheritance of novel susceptibility alleles for adenomatous polyposis of&#xD;
           the colon with colon neoplasia in these patients.&#xD;
&#xD;
        -  Correlate colon neoplasia susceptibility with the presence of COX-2, sPLA2, and DNMT&#xD;
           genes in these patients.&#xD;
&#xD;
        -  Identify a novel gene that governs increased susceptibility to colon adenoma and cancer&#xD;
           in the genome of these patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2001</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">600</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>Patients donate blood samples for analysis of colorectal susceptibility genes. Patients also complete a questionnaire regarding family cancer history.&#xD;
A certificate of confidentiality protecting the identity of research participants in this project has been issued by the National Cancer Institute.&#xD;
Participants do not receive the results of the genetic testing, and the results do not influence the type or duration of treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>cytogenetic analysis</intervention_name>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene mapping</intervention_name>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>microarray analysis</intervention_name>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with colon cancer or polyps age 70 or under. Specifically, patients&#xD;
        previously enrolled on CLB-9581, CLB-89803 and CLB-80001.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of colon cancer or polyps at age 70 or under&#xD;
&#xD;
          -  Has a living full sibling with diagnosis of colon cancer or polyps at age 70 or under&#xD;
&#xD;
          -  No history of familial adenomatous polyposis syndrome&#xD;
&#xD;
          -  No hereditary nonpolyposis colon cancer, according to Amsterdam criteria&#xD;
&#xD;
          -  No known I1370K adenomatous polyposis of the colon susceptibility variant&#xD;
&#xD;
          -  Enrolled on 1 of the following clinical trials:&#xD;
&#xD;
               -  CLB-9581&#xD;
&#xD;
               -  CLB-89803&#xD;
&#xD;
               -  CLB-80001 NOTE: Patients do not need to be receiving protocol therapy. Patients&#xD;
                  who are outside the treatment protocol's follow-up range are eligible. Patients&#xD;
                  who discontinued therapy for any reason, including toxic effects, are eligible.&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  70 and under at diagnosis&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No significant psychiatric illness that would preclude giving informed consent&#xD;
&#xD;
          -  No inflammatory bowel disease (in patient or sibling)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Monica M. Bertagnolli, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Dana-Farber/Brigham and Women's Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wayne Memorial Hospital, Incorporated</name>
      <address>
        <city>Goldsboro</city>
        <state>North Carolina</state>
        <zip>27534</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <study_first_submitted>March 6, 2003</study_first_submitted>
  <study_first_submitted_qc>March 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2003</study_first_posted>
  <last_update_submitted>July 12, 2016</last_update_submitted>
  <last_update_submitted_qc>July 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the colon</keyword>
  <keyword>stage I colon cancer</keyword>
  <keyword>stage II colon cancer</keyword>
  <keyword>stage III colon cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

